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Abstract. Sickle cell disease (SCD; ORPHA232; OMIM # 603903) is a chronic and invalidating 
disorder distributed worldwide, with high morbidity and mortality. Given the disease complexity 
and the multiplicity of pathophysiological targets, development of new therapeutic options is 
critical, despite the positive effects of hydroxyurea (HU), for many years the only approved drug 
for SCD.  
New therapeutic strategies might be divided into (1) pathophysiology-related novel therapies and 
(2) innovations in curative therapeutic options such as hematopoietic stem cell transplantation and 
gene therapy. The pathophysiology related novel therapies are: a) Agents which reduce sickling 
or prevent sickle red cell dehydration; b) Agents targeting SCD vasculopathy and sickle cell-
endothelial adhesive events; c) Anti-oxidant agents. 
This review highlights new therapeutic strategies in SCD and discusses future developments, 
research implications, and possible innovative clinical trials.  
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Introduction. Sickle cell disease (SCD) is a 
hemoglobinopathy which affects approximately 
100,000 individuals in the United States and almost 
20,000-25,000 subjects in Europe, mainly immigrants 
from endemic areas such as Sub-Saharan Africa to 
European countries.1-3  Estimates of the number of 
affected newborn in 2010 are of approximately 312,302 
subjects  with 75.5% being born in Africa.4 The 
invalidating impact of SCD on patient survival, quality 
of life and cost for health systems,2 requires the 
development of new therapeutic options to treat sickle 
cell related acute and chronic complications.   
SCD is caused by a point mutation in the β-globin 
gene resulting in the synthesis of pathological 
hemoglobin S (HbS). HbS displays peculiar biochemical 
characteristics, polymerizing when deoxygenated with 
associated reduction in cell ion and water content (cell 
dehydration), increased red cell density and further 
acceleration of HbS polymerization (Figure 1).5-7 
Pathophysiological studies have shown that dense, 
dehydrated red cells play a central role in acute and 
chronic clinical manifestations of SCD, in which 
intravascular sickling in capillaries and small vessels 
leads to vaso-occlusion and impaired blood flow with 
ischemic/reperfusion injury.5,8-10 In microcirculation, 
vaso-occlusive events (VOC) result from a complex and 
still partially known scenario, involving the interactions 
between different cell types, including dense red cells, 
reticulocytes, abnormally activated endothelial cells, 
leukocytes, platelets and plasma factors (Figure 1).5,9-13 
Acute VOCs have been associated with increased 
expression of pro-adhesion molecules such as vascular 
adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule-1 (ICAM-1) or selectins (Figure 1).5,9,11,12,14,15 
These molecules are important in recruitment and 
adhesion of both neutrophils and sickle red cells to the 
abnormally activated vascular endothelial surface.11,16 In 
addition,   the   presence   of   free   Hb   and   free   heme
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Figure 1. Schematic diagram of the mechanisms involved in the pathogenesis of acute sickle cell related vaso-occlusive events. These involve 
the adherence of sickle red blood cells (RBCs) or reticulocytes and neutrophils to the abnormally activated endothelial cells, with the 
participation of activated and phosphatidyl- Serine (PS)-rich platelets (PLTs), activation of the coagulation system, and activation of a cytokine 
storm. PS: Phosphatidyl-Serine; TSP: thrombospondine; vWF: von Willebrand factor; BCAM/LU: Lutheran blood group protein; ICAM-4: 
Landstein-Weiner (LW) blood group glycoprotein; MPs: microparticles; Mac1: β2 integrins (αMβ2 or CD11b/CD18); ESL-1: neutrophil E-
selectin ligand -1; Hb: hemoglobin; ROS: reactive oxygen species; iNKT: invariant natural killer T cells; ET-1: endothelin-1; NO: nitric oxide 
(modified from De Franceschi L et al. Seminars in Thrombosis, 37: 266; 2011).   
 
contribute to the local reduction of nitric oxide (NO) 
bioavailability, establishing an endovascular high pro-
oxidant and pro-inflammatory environment. This is 
associated with modulation of innate immunity and 
increased iNKT lymphocytes, increase levels of 
vascular active cytokines such as endothelin 1, 
combined with the final contribution of platelets (Figure 
1).5,9,14,17-20 
 
Hydroxyurea is the Gold- Standard Treatment for 
Sickle Cell Disease. Hydroxyurea or hydroxycarbamide 
(HU) is the key therapeutic tool for SCD approved by 
Food and Drug Administration (FDA) and European 
Medical Agency (EMEA). US and European guidelines 
highlighted that HU should be available for all SCD 
patients from pediatric to adult populations.21,22 
Studies in SCD show a multimodal action of HU, 
which (i) increases HbF production, resulting in delayed 
HbS polymerization; (ii) reduces hemolysis and increase 
NO availability targeting cGMP production; (iii) 
modulates endothelial activation and reduces neutrophil 
counts, contributing to the reduction of chronic 
inflammation (Figure 2).23-27 Long-term use of HU has 
been shown to be safe and well-tolerated in large cohorts 
of children and adults with SCD, reducing mortality and 
morbidity of both children and adult patients.21,28-31 
Indeed, HU reduces (i) the frequency of VOC and the 
rate of hospitalization; (ii) the incidence of ACS; (iii) the 
transfusion requirements; and (iv) the severity of 
dactilitis in SCD pediatric population.21,32-36 HU might 
also be used in combination with transfusion regimen in 
selected SCD population such as SCD children with 
progressive cerebrovascular disease in the absence of 
antigen- matched sibling donor.37 Furthermore, recent 
reports propose HU as acceptable alternative to chronic 
transfusion regimen in SCD patients with history of 
abnormalities at the transcranial doppler scan (TCD), 
used to screen for cerebrovascular disease in pediatric 
patients.38-40 This requires a close follow-up by TCD 
scan every 3 months, with the possibility to switch-back 
to chronic transfusion regimen if abnormal transcranial 
velocities are again documented.38-40 Noteworthy, 
increase reticulocyte count before HU treatment and 
high leukocyte count after HU have been identified as 
risk factor for reversion to abnormal TCD velocities in 
SCD pediatric patients. Thus, again chronic 
inflammation and vasculopathy seems to be key 
determinants of severe chronic complications in   
SCD.38-40 
Although HU should be available for all SCD subjects, 
the major limitation is the poor adherence of adults SCD 
patients to HU therapy. Different studies have identified 
multiple factors to be involved in reduced adherence of 
SCD patients to HU such as (i) chronicity of the 
treatment; (ii) socio-economic reasons; and (iii) 
adhesion barriers related to the transition from pediatric 
to adult care system.41-44 
The dissemination of the use of HU is particularly 
important in underdeveloped countries with high 
incidence of SCD such as in the sub-Saharan African 
areas.45 Recently, Opoka et al. reported safety of use for 
HU at the dosage of ~20 mg/Kg/d in African children 
from Uganda, a malaria endemic area (NOHARM study, 
NCT01976416).46 This study further supports the 
importance of HU as a front-line medical treatment for 
SCD patients all over the world.  Noteworthy, in 
geographical context where frequent hematologic 
monitoring is not available, Toya et al. have recently 
reported the beneficial effects of low dose HU (10 
mg/Kg/d) on SCD acute clinical manifestations in 
Nigerian patients.47 
 
Novel Therapeutic Approaches to Treat Sickle Cell 
Disease. In the last two decades, the availability of 
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Figure 2. Schematic diagram of multimodal therapeutic action of hydroxyurea (HU) in sickle cell disease.  ROS: reactive oxygen species; Hb: 
hemoglobin; NO: nitric oxide; HbS: sickle hemoglobin; HbF: fetal hemoglobin.  
 
mouse models for SCD has allowed both 
characterization of the pathogenesis of sickle cell related 
organ damage(s) and identification of pathophysiology-
based new therapeutic options in addition to 
HU.5,7,11,12,48-50 
As shown in Table 1, pathophysiology related novel 
therapies for SCD can be divided into: 
• Agents which reduce/prevent sickle red cell 
dehydration or red cell sickling or HbF inducers;  
• Agents targeting SCD vasculopathy and sickle cell-
endothelial adhesive events; 
• Anti-oxidant agents. 
 
Agents Which Reduce/Prevent Sickle Red Cell 
Dehydration and Sickling. Different agents targeting 
sickle red cells have been developed to prevent or limit 
HbS polymerization or to block the mechanism(s) 
involved in red cell dehydration.14,18,19,48,51-55 Targeting 
the reduction of circulating dense red cells and/or 
sickled red cells is very important, since these cells are 
easily trapped in microcirculation and participate to the 
pathogenesis of acute VOC.  
Recent reports indicate GBT440, an oral direct anti-
sickling agent, to be beneficial in SCD. GBT440 (or 
voxelotor) blocks HbS intermolecular contacts, 
preventing the generation of HbS fibers and red cell 
sickling.56-60 GBT440 has been shown (i) to ameliorate 
in vitro SCD red cell features such as red cell 
deformability or viscosity and (ii) to improve sickle red 
cell survival with decrease reticulocyte count.56-60 
Preliminary data on phase I/II double blind placebo 
study with GBT440 in healthy volunteers and few SCD 
patients show safety and tolerability of GBT440 
associated with an amelioration of hemolytic indices and 
a reduction in reticulocyte count 
(#NCT02285088).55,61,62 Blyden et al. have reported the 
compassionate use of voxelotor, at the dosage of 900 
mg/d up to 1500 mg/d for 24 weeks in a small group of 
subjects with severe untreatable SCD.  Voxelotor 
beneficially impacts SCD patient well-being with a 
reduction in number of hospitalization for severe VOC 
compared to patient’s clinical history.63 These data 
further support the on-going phase III clinical trial on 
voxelotor in a larger population of SCD patients (HOPE; 
#NCT03036813).  
 
Agents Targeting SCD Vasculopathy and Sickle Cell-
Endothelial Adhesive Events. SCD is not only a 
hemolytic anemia but also a chronic inflammatory 
disorder characterized by abnormally activated vascular 
endothelial cells, amplified inflammatory response, and 
the release of soluble factors, which promote abnormal 
adhesive interactions between erythrocytes, endothelial 
cells, and neutrophils.5,7,10,12,64,65 An increased number of  
circulating, abnormally activated endothelial cells has 
been identified in SCD patients during acute VOCs, 
indicating the presence of chronic vasculopathy, 
worsened by acute events.66 Thus, SCD is characterized 
by a chronic inflammatory vasculopathy that favors the 
recruitment of leukocytes and the entrapment of dense 
red cells with the generation of heterotypic aggregates 
(thrombi) with ischemic/reperfusion local damage. 
In this context, the major objectives of therapeutic 
strategies targeting sickle cell vasculopathy are to 
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reduce or prevent vascular endothelial activation and 
damage.  The end-point of anti-adherence therapy, 
alternatively, is to interfere with the initialization and/or 
amplification of adhesive events.  
In SCD, agents targeting SCD vasculopathy and 
sickle cell-endothelial adhesive events (Figure 3) can be 
divided into: 
 
i. Molecules targeting hemolysis-induced 
vasculopathy; 
ii. Agents that modulate the abnormal vascular tone; 
iii. Agents interfering with red cell vascular adhesion 
events. 
 
i. Molecules targeting hemolysis-induced 
vasculopathy. The chronic hemolytic anemia of SCD is 
for one-third intravascular and for two-third 
extravascular, via the reticulo-endothelial systems. Free 
Hb is present in the peripheral circulation of SCD 
patients, reacting with plasma nitric oxide (NO) with 
production of reactive oxygen species (ROS) and 
generation of MetHb. This is a key step for the release 
of free heme.9,67,68 
The physiological systems binding free Hb or free 
heme are haptoglobin (Hp) and hemopexin (Hx), 
respectively.
 
Table 1. Novel Therapeutic Targets in SCD and Experimental Treatments.
Targets Agents and Mechanism of Action References 
Sickle red cell 
dehydration or red 
cell sickling 
Anti-sickling agent  
GBT440 is an oral direct anti-sickling agent, to be beneficial in 
SCD. GBT440 (or voxelotor) blocks HbS intermolecular contacts, 
preventing the generation of HbS fibers and red cell sickling 
((#NCT02285088). on-going phase III clinical trial on voxelotor in 
a larger population of SCD patients (HOPE; #NCT03036813).  
56-60 
SCD vasculopathy 
and sickle cell-
endothelial 
adhesive events 
Molecules 
targeting 
hemolysis-induce 
vasculopathy 
Haptoglobin (Hp) and hemopexin (Hx) respectively binding free 
Hb or free heme 
67-76 
Agents that 
modulate the 
abnormal vascular 
tone 
- NO donors such as nitrate or NCX1443 or L-Arginine 
- Bosentan: Endothelin-1 (ET-1) receptors’ blocker 
18, 77-81, 
84, 85, 89, 
90, 91 
Agents interfering 
with red cell 
vascular adhesion 
events 
- Molecules interfering with the physical properties of the red cell-
endothelial adhesion process. RheothRx (Poloxamer 188), a non-
ionic surfactant copolymer was shown to improve microvascular 
blood. Mast Therapeutics announced in 2016 negative results for a 
new phase III trial with Vepoloxamer (MST-188).  
96-99 
- Molecules specifically interfering with sickle cell-endothelial 
adhesive mechanisms. Selectins blockers: (i) pan-Selectin 
antagonist (GMI-1070, rivipansel; #NCT01119833); (ii) 
humanized anti-P-Selectin antibody (SelG1, crinalizumab; 
SUSTAIN, #NCT0185361); (iii) P-selectin-aptamer; and (iv) 
sevuparin. 
11, 12, 15, 
50, 65, 104, 
107-112 
-      Molecules modulating inflammatory pathways involved in sickle 
cell endothelial adhesion. (i) Regadenoson, a selective A2A 
adenosine receptor agonist, reduces iNKT activation but it fails in 
interfering with the severity of the acute clinical manifestations of 
SCD patients enrolled in randomized phase II clinical trial 
(#NCT01788631) 
(ii) Antibodies against iNKT cells (NKTT120) (#NCT01783691). 
(iii) omega-3 fatty acids supplementation. A phase II multicenter 
randomized double-blind placebo-controlled study in SCD 
patients reported that ω-3 fatty acid supplementation reduced pain 
episode in SCD subjects (SCOT, #NCT02973360). 
14, 15, 99, 
115-128 
- Molecules affecting platelet function. Ticagrelor, a direct anti-
platelet agent (HESTIA1, #NCT02214121). A phase III clinical 
trial with ticagrelor in adults with SCD is on-going 
(#NCT02482298) 
11, 131 
Oxidative stress Anti-oxidant agents 
- N-Acetyl-Cysteine (NAC), an exogenous thiol donor. A clinical 
trial with high dose of NAC during acute VOCs related to SCD is 
ongoing (#NCT 01800526). 
- L-Glutamine. Glutamine is involved in GSH metabolism. A 
multicenter, randomize, placebo-controlled double-blind phase III 
clinical trial with L-glutamine (0.3 g/Kg twice a day) 
supplementation reduced the mean number and length of 
hospitalization, associated with increased median time to the first 
crisis.  
134-140 
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Figure 3. Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of sickle cell disease 
and sickle cell vasculopathy. Hp: haptoglobin; Hx: hemopexin; NAC: N-Acetyl-cysteine; Ab: antibody; ROS: reactive oxygen species; iNKT: 
invariant natural killer T cells; NKTT120: humanized monoclonal antibody specifically depleting iNKT; NO: nitric oxide; ET-1: endothelin-
1; ET-R: endothelin-1 receptor.  
 
In SCD patients, both Hp and Hx levels are significantly 
reduced in steady state compared to healthy controls; 
they further decrease during acute VOCs.67,69 The highly 
pro-oxidant environment with the presence of free heme 
and free Hb promotes inflammation and abnormal 
vascular activation with increased expression of 
adhesion vascular molecules such as VCAM-1, ICAM-
1 or E-selectin.67,69 Studies in mouse models for SCD 
have shown that free heme induces vascular stasis and 
leukocyte extravasation with the trapping of dense red 
cells and neutrophils in microcirculation.70-72    
In human SCD patients, free Hb and free heme 
increase during acute VOCs with further reduction in Hp 
and Hx levels (Figure 1).72,73 Noteworthy, Hp levels 
correlate with pulmonary hypertension,67 suggesting 
that the blockage of free-Hb by Hp might possibly affect 
SCD related organ damage. In mouse models for SCD, 
the infusion of Hp has been shown to prevent vascular 
stasis. Encouraging data from small, in vivo human 
studies with infused Hp show that Hp protects the 
kidneys from free Hb-related tubular damage in patients 
who have undergone cardiopulmonary surgery or 
endoscopic sclerotherapy.67 Few case reports are present 
in the literature on the use of Hp in patients with 
hemolytic crisis and inherited red cell disorders.67,74 
Thus, Hp might be as a possible new therapeutic tool to 
be further explored in SCD.   
In the complex scenario of the pathogenesis of SCD 
vasculopathy, Hx, a high affinity heme binding protein, 
represents another interesting molecule that might be 
explored as a novel therapeutic option (Figure 1). The 
supplementation of Hx in mouse models for SCD has 
been shown to reduce heme induced oxidative stress, 
vascular endothelial injury, inflammation, and vascular 
stasis.9 Recently, a link between increased free heme and 
complement activation has been reported in cell- and 
animal-based model for SCD.75 Hx significantly reduces 
complement deposition in kidney from humanized SCD 
mice, highlighting the importance of controlling free 
heme plasma level as additional tool to limit 
inflammatory vasculopathy and related severe organ 
damage in SCD. The importance of optimal levels of Hp 
and Hx is also supported by a recent report on the use of 
therapeutic plasma exchange in SCD with severe VOC, 
resistant to red cell exchange.76  
Further studies need be carried out to develop and 
understand the potential clinical use of Hp and/or Hx in 
management of severe complication related to excess of 
free heme in SCD patients.   
i. Agents that modulate the abnormal vascular 
tone. Vascular tone results from the balance between 
vaso-dilatatory factors such as nitric oxide (NO) and 
vaso-constrictor factors such as the endothelin-1  (ET-1) 
system (Figure 1).18,77-81 In SCD, reduced NO local 
bioavailability, a consequence of the presence of free 
Hb, contributes to chronic vaso-constriction and 
amplifies the expression of vascular adhesion 
molecules.77,82,83 In addition, the release of arginase in 
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peripheral circulation by sickle red cells during chronic 
hemolysis, subtracts arginine from the urea cycle in 
endothelial cells, and further contributes to NO 
deficiency.77,82-85 Plasma NO metabolites are decreased 
in SCD patients during acute VOCs and decreased 
exhaled NO has also been reported. Thus, therapeutic 
strategies to supplement or modulate NO might 
beneficially interfere with the pathogenesis of acute 
SCD related clinical manifestations such as VOCs. 
Initial trials showed some positive, encouraging effects 
of inhaled NO on acute VOCs.82,86,87 However, a 
subsequent multicentric, double-blind, randomized 
placebo-controlled study in SCD with VOCs using 
inhaled NO showed no clinically significant effects.82 
New NO donors such as nitrate or NCX1443 need to be 
further evaluated in humanized animal-based pre-
clinical studies.83,88 Another possible strategy to increase 
NO production in SCD is the supplementation of L-
Arginine. Oral L-Arginine (i) decreases artery 
pulmonary pressure in SCD; (ii) improves leg ulcers; 
and (iii) contributes in pain control in SCD.84,85,89 The 
co-administration of L-Arginine with HU has been 
reported to increase levels of nitrate, suggesting L-
Arginine as an adjuvant molecule in treatment of 
SCD.84,85,89 
Endothelin-1 is a potent vasoconstrictor and 
bronchoconstrictor, whose plasma and urinary values 
are increased in SCD subjects in steady state and during 
acute VOCs.18,90,91 In a mouse model for SCD, the ET-1 
receptors’ blocker, bosentan, prevented hypoxia induced 
organ damage and affect neutrophil mediated 
inflammatory response, suggesting the modulation of 
the ET-1 system as an additional therapeutic option to 
interfere with the pathogenesis of SCD related clinical 
manifestation(s).18,92,93 It is of interest to note that 
increased ET-1 and high ET-1 levels have been shown 
to positively correlate with pain rating in children with 
SCD.94 This has been recently investigated in 
humanized mouse model for SCD, showing that 
endothelin receptor-type A might be involved in 
inflammatory mediated pain component throughout the 
modulation of Nav1.8 channel in primary sensing 
neurons.95 
 
ii. Agents interfering with red cell vascular 
adhesion events. In SCD, anti-adherence therapeutic 
strategies might represent an interesting, novel 
therapeutic strategy to prevent the generation of acute 
VOCs and to lessen SCD related organ damage (Figure 
1 and 3). The anti-adherence therapeutic options might 
be divided into three groups based on their mechanism 
of action: 
a) Molecules interfering with the physical properties 
of the red cell-endothelial adhesion process; 
b) Molecules specifically interfering with sickle cell-
endothelial adhesive mechanisms; 
c) Molecules modulating inflammatory pathways 
involved in sickle cell endothelial adhesion; 
d) Molecules affecting platelet function. 
 
a) Molecules interfering with the physical 
properties of the red cell-endothelial adhesion process. 
RheothRx (Poloxamer 188), a non-ionic surfactant 
copolymer was shown to improve microvascular blood 
flow by lowering viscosity and frictional forces. 
RheothRx was shown some beneficial effects on pain 
intensity and duration of hospitalization in a pilot study 
on SCD patients experiencing moderate to severe vaso-
occlusive crisis.96 RheothRx was tested in a phase III 
clinical study for treatment of VOCs in SCD. Although 
P188 has been shown to shorten the duration of pain 
crisis, its effects on acute events were limited.97,98  Mast 
Therapeutics announced in 2016 negative results for a 
new  phase III trial  with Vepoloxamer (MST-188), a IV 
agent tested to assess its effect on reducing the duration 
of vaso-occlusive crises.99 
 
b) Molecules interfering with sickle cell-
endothelial adhesive mechanisms. Recent studies in 
SCD have identified different mechanisms involved in 
sickle cell-endothelium adhesive events, which may be 
of therapeutic relevance (Figure 1): (i) the integrin α4β1 
receptor of fibronectin and the vascular adhesion 
molecule-1 (VCAM-1), E-selectin and P-selectin; (ii) 
the thrombospondin and/or collagen and receptor CD36, 
present on the surface of endothelial cells, platelets and 
reticulocyte-rich subpopulations of normal and sickle 
red cells; (iii) the sulfate glycolipids, which bind 
thrombospondin, von-Willebrand factor multimer and 
laminin; (iv) the Lutheran blood group proteins 
(BCAM/LU), whose  expression is increased in red cells 
from SCD patients; (v) the ICAM-4 (Landstein-Weiner 
blood group glycoprotein-LW), which binds αVβ3 
integrin receptors; and (vi) the exposure of PS detectable 
in a subpopulation of sickle red cells, which participates 
both in cell-cell adhesion to activated vascular 
endothelium surface and in the activation of a 
coagulation system. Monoclonal antibodies against the 
adhesion molecules or short synthetic peptides 
interfering with ICAM-4 or αVβ3 integrin have been 
shown to reduce adhesion events in SCD mouse models 
(Figure 1). It is of interest to note that antibodies against 
adhesion molecules block the heme induced vascular 
stasis, supporting again the connection between heme, 
vasculopathy, and adhesion events in SCD.68,100,101 
Among the agents interfering with red cell vascular 
adhesion events, the blockade of adhesion mechanisms 
through interference with Selectins seems to be a novel 
powerful therapeutic option for clinical management of 
SCD. Selectins are a family of molecules mediating 
adhesion of blood cells with activated vascular 
endothelial cells. and play a key role in leukocyte 
recruitment as well as in sickle red cell adhesion to 
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inflammatory activated vascular endothelium. In 
addition, studies have shown that P-selectin are 
increased in plasma of SCD patients.65,102-106 Different 
therapeutic strategies have been developed, to block 
selectins: (i) pan-Selectin antagonist (GMI-1070, 
rivipansel); (ii) humanized anti-P-Selectin antibody 
(SelG1, crinalizumab); (iii) P-selectin-aptamer; and (iv) 
sevuparin.11,12,15,50,65,104,107-112 Rivipansel is a 
glycomimetic pan-selectin antagonist, which was tested 
in phase-I and -II studies in SCD. Rivipansel showed a 
safe profile, reducing the levels of E-Selectin in SCD 
patients during acute VOCs.107,113 In phase II study, 
rivipansel beneficially affected the number of pain crisis 
in a small number of SCD subjects (#NCT01119833). 
However, these data were obtained including  some SC 
patients, which generates some difficulties in  their 
interpretation. An on-going phase II study is focused on 
SCD children.  
Crinalizumab is a humanized P-Selectin antibody, 
which has been tested in a multinational double-blind 
placebo-controlled trial (SUSTAIN, 
#NCT0185361).15,111 SCD subjects (SS, SC, S+ and S0 
genotype) were treated with crinalizumab either 2.5 or 5 
mg/Kg every 4 weeks. Crinalizumab at the dosage of 5 
mg/Kg every 4 weeks reduced the number of pain crisis 
and increased the time between VOCs in SCD 
independently from possible preceding HU 
treatment.15,111,112 
An additional strategy targeting P-Selectins is 
represented by the use of low molecular weight 
heparins, such as tinzaparin, which has been shown to 
block the P-Selectin system and to reduce the duration 
and the severity of VOCs in few cases of SCD 
patients.12,50 Sevuparin is a derivative of low-molecular 
weight heparin, lacking anticoagulant activity and it has 
been evaluated in SCD.109,114 Sevuparin acts on multiple 
targets: (i) P and L-selectins; (ii) thrombospondin- 
Fibronectin-Von Willebrand factor; and (iii) sickle-
leukocyte-endothelial cells interaction. A phase II 
multicenter international trial on sevuparin in acute 
VOCs is ongoing.  
 
c) Molecules modulating inflammatory pathways 
involved in sickle cell endothelial adhesion. Another set 
of novel therapeutic option is represented by agents 
modulating the inflammatory pathways that participate 
to adhesion events in SCD.  
Studies in different models of 
hypoxia/reoxygenation stress have shown that 
adenosine is released from cells and interacts with A (1-
3) receptors (AR), which are present on endothelial 
cells, leukocytes and iNKT cells. This promotes the 
activation of the transcriptional factor NF-kB, which 
orchestrates the inflammatory response. iNKT are a 
subgroup of T lymphocytes that affects both innate and 
adaptive immunity, participating to inflammatory 
cascade.115-117 Increased iNKT circulating cells have 
been observed in SCD subjects on both steady state and 
during acute VOCs. Antibodies against iNKT cells 
(NKTT120) have been developed, based on the key role 
that adhesion and inflammation are involved in the 
pathogenesis of severe acute complication of SCD 
(#NCT01783691).15,99,115 Field et al. recently reported 
the failure of regadenoson in reducing iNKT activation 
and in interfering with the severity of the acute clinical 
manifestations of SCD patients enrolled in randomized 
phase II clinical trial (#NCT01788631).118 
An attempt to target inflammatory vasculopathy and 
to modulate inflammatory response has been made 
based on the evidences in other diseases such as in 
cardiovascular disease looking to dietary manipulation 
with omega-3 fatty acids (ω-3 PUFAs).  
Supplementation with omega-3 fatty acids has been 
reported to (i) beneficially affect red cell membrane 
lipid composition; (ii) modulate soluble and cellular 
inflammatory response and coagulation cascade; and 
(iii) to favor NO production.119-122 In SCD, the fatty acid 
profile of sickle erythrocytes is altered compared to 
healthy controls, with a relative increase in the ratio of 
ω-6 to ω-3 PUFAs, in agreement with sustained chronic 
inflammation.123,124 In humanized mouse model for 
SCD, PUFA supplementation protects against acute 
sickle cell-related lung and liver damages during 
hypoxia/reoxygenation induced VOCs.14 A phase II 
multicenter randomized double-blind placebo-
controlled study in SCD patients reported that ω-3 fatty 
acid supplementation reduced pain episode in SCD 
subjects (SCOT, #NCT02973360).125-128 
 
d) Molecules affecting platelet function. The role 
of platelets in clinical manifestations of SCD on both 
steady state and acute events has been only partially 
characterized and much still remains to be 
investigated.5,11,50 Early evidence on the beneficial 
effects of ticlopidine on reducing the rate of pain crisis 
highlighted the potential role of platelet activation and 
aggregation during acute events in SCD.129 However, a 
multicentric phase 2 study on prasugrel, a third-
generation anti-platelet agent, in adult with SCD showed 
a reduction of platelet activation without change in pain 
rate.130 Recently, ticagrelor, a direct anti-platelet agent 
with some effects on vascular tone and inflammatory 
response has been evaluated in a dose-finding study on 
SCD children (HESTIA1, #NCT02214121).11,131 
Ticagrelor was well tolerated without significant drug 
related adverse events, in particular no hemorrhagic 
events were reported. Noteworthy, in SCD children 
ticagrelor induced platelet inhibition similar to that 
reported in adults with acute coronary disease.131  A 
phase III clinical trial with ticagrelor in adults with SCD 
is on-going (#NCT02482298).11,131 
 
Anti-Oxidant Agents and Sickle Cell Disease. SCD is 
also characterized by a highly pro-oxidant environment 
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due to the elevated production of reactive oxygen 
species (ROS) generated by increased levels of 
pathological free heme and iron and a reduction in anti-
oxidant systems such as GSH (Figure1).5,7,12,132,133 N-
Acetyl-Cysteine (NAC), an exogenous thiol donor, has 
been studied both in vitro and in vivo in SCD patients. 
NAC supplementation (1,200-2,400 mg/day) was 
shown to reduce the formation of dense red cells and the 
rate of hemolysis and to increase GSH levels in SCD 
subjects. However, Sins et al. have recently reported a 
randomized, placebo-, double-blind trial 
(#NCT01849016) on NAC in SCD. Although the study 
shows a failure of NAC in affecting acute clinical 
manifestations of SCD, the Authors point out that the 
low adherence of SCD to NAC treatment might be 
responsible for the reduced biological effect of NAC in 
SCD. A clinical trial with high dose of NAC during 
acute VOCs related to SCD is ongoing (#NCT 
01800526).134-136 
L-Glutamine is a likely anti-oxidant agent in SCD. 
Glutamine is involved in GSH metabolism since it 
preserves NADPH levels required for GSH recycling, 
and it is the precursor for nicotinamide adenine 
dinucleotide (NAD) and arginine.137-139 A first 
randomized, double blind, placebo-controlled parallel 
group trial with L-glutamine supplementation in SCD 
patients showed reduction in number of hospitalization 
compared to historic patients data.138 Recently, a 
multicenter, randomize, placebo-controlled double-
blind phase III clinical trial with L-glutamine (0.3 g/Kg 
twice a day) involving 230 SS/Sbeta0 patients with > 2 
pain crisis showed that L-glutamine supplementation 
reduced the mean number and length of hospitalization, 
associated with increased median time to the first 
crisis.137   Both studies have several limitations such as 
(i) the high rate of patient drop-out; (ii) the presence of 
fatal events due to multiorgan failure in L-glutamine 
arm; (iii) the lack of effects on hematologic parameters 
and hemolytic indices; and (iv) the absence of clear data 
on L-glutamine mechanism of action.137,140 Since no 
information are available on log-term use of L-
glutamine supplementation as well on the systemic 
effects of L-glutamine, the sickle cell scientific 
community should use caution in prescribing L-
glutamine supplement for both adult and pediatric SCD 
patients.140 Future studies are required to further define 
the role of anti-oxidant treatments in the clinical 
management of SCD subjects.  
 
Curative Options in Sickle Cell Disease. In the last 
two decades, progresses on hematopoietic stem cell 
transplantation (HSCT) strategies have allowed to offer 
a new curative option to patients with SCD. The major 
limitation in diffusion of HSCT is (i) the availability of 
leukocyte antigen (HLA)-matched sibling donor; (ii) the 
toxicities associated with myeloablative conditioning; 
and (iii) inflammatory vasculopathy.141-145 Recently, 
lentiviral gene therapy has been reported to be safe and 
to positively impact hematologic phenotype in a child 
with SCD.146 Different clinical trials on gene therapy in 
SCD are on-going in various countries.141-144 
Finally, the development of CRISPR/Cas9 genome 
editing (GE) strategy has been reported to represent a 
new potential therapeutic tool for genetic correction of 
SCD.147-149 However, in SCD GE is still limited to cell- 
and/or animal-based studies. 
 
Conclusions. In conclusion, the emerging picture for 
new treatment of SCD is that formation of dense red 
cells, vasculopathy, adhesion events and inflammation 
as well as oxidative stress might constitute new 
pharmacological targets (Figure 3).   
Promising data have been reported on new 
therapeutic tools interfering with P-selectin and 
modulating inflammatory vasculopathy. However, some 
concerns have been expressed about possible reductions 
of  appropriate inflammatory responses to pathogens, 
although the initial trials did not show any signal in this 
direction. A new field of combinatorial therapy for SCD 
will require a holistic approach, considering the 
improvement of patient quality of life as an important 
outcome in designing new clinical studies.  
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